The Whitehouse has released a Global Health Security Strategy. The Strategy outlines actions the Administration will take to prevent, detect, and respond to infectious disease threats, whether naturally occurring, accidental, or deliberate.
This publication summarizes two workshops held by the US National Academies of Sciences, Engineering, and Medicine to examine lessons from influenza pandemics and other major outbreaks, understand the extent to which the lessons were learned, and discuss how the lessons could be applied further to ensure that countries are sufficiently ready for future pandemics.
A new report maintains there are gaps in pandemics related events readiness.
On February 26, 2003, Carlo Urbani, an infectious diseases specialist in the World Health Organization's (WHO's) country office in Vietnam, was called to the French Hospital in Hanoi to examine a grievously ill Chinese-American businessman. Johnny Chen had been admitted with severe breathing difficulties shortly after stepping off a flight from Hong Kong and was being nursed in intensive care, where x-rays revealed ominous shadows on his lungs.
Creating mathematical and computational models of infectious diseases like pandemic flu gives government and policy-makers a toolkit to respond to this ever-present threat.
The World Health Organization (WHO) developed the Global Influenza Strategy for 2019–2030 to enhance global and national pandemic preparedness, to combat the ongoing threat of zoonotic influenza, and to improve seasonal influenza prevention and control in all countries.
The World Health Organization (WHO) has released a Global Influenza Strategy for 2019-2030 aimed at protecting people in all countries from the threat of influenza.
In a move to defeat the next pandemic, the CEPI (Coalition for Epidemic Preparedness Innovations) has reportedly signed an agreement with CureVac, a German biopharmaceutical firm. The duo plan to develop a vaccine printing technology, with an aim to produce shots against various diseases.
Researchers have developed a mathematical framework to estimate the value of investing in developing and conserving an antibiotic to mitigate the burden of bacterial infections caused by resistant Staphylococcus aureus during a pandemic influenza outbreak.
The H5N1 avian influenza antigen and adjuvant maintained their functional integrity in the National Pre-Pandemic Influenza Vaccine Stockpile (NPIVS), according to testing by the US Biomedical Advanced Research and Development Authority (BARDA).